RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.

Ventus Therapeutics, a US-based small molecule drug developer, completed a $100m series B round yesterday led by investment manager RA Capital Management. GV, a corporate venture capital subsidiary of internet and technology group Alphabet, also took part in the round, as did Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.